Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
Gildan After Hanes - A Post-M&A Long with Defined Targets and Guardrails
Use integration readouts, debt progress and Bangladesh capacity ramp as the playbook for a position trade
Gildan (GIL) has closed the HanesBrands acquisition and sits at an inflection where execution — not deal odds — will determine the next leg of the...
Cenovus: Positioning for a Breakout in 2026
Scale, buybacks and a capital plan give Cenovus (CVE) a clear playbook — trade it as a directional long into 2026 with defined risk controls.
Cenovus just closed the MEG Energy deal, refreshed buybacks and set a 2026 capital plan while accessing $2.6B of debt markets. The stock is trading ne...
Illinois Tool Works: Buy the Soft Patch — Growth Re-acceleration, PLS Drag Fading, and Improving Cash Returns
Actionable trade: accumulate ITW on a pullback; stop tight, targets based on margin recovery and multiple re-rating
ITW looks like a durable industrial with a temporary earnings drag. Recent quarters show resilient revenue (~$4.0bn/qtr), strong operating cash flow (...
Navan: AI That Actually Lowers Costs - A Tactical Long with Defined Stops
AI-driven travel and expense workflow with meaningful unit economics; beat-and-hold setup if management converts product traction into consistent margin improvement
Navan is an AI-first travel and T&E platform showing strong top-line engagement (Q3 revenue $194.9M, gross margin healthy) and unusually strong liquid...
GameStop as a Cash-Heavy Holding Play: Why the Balance Sheet Is the Growth Story
A trade idea: long a cash-rich GameStop with a tactical entry, tight stop, and layered targets — play the balance sheet while management executes transformation
GameStop has evolved from a strip-mall retailer to, in effect, a cash-rich holding company with operating businesses. With roughly $10.34B in total as...
ATI: Play the Aerospace & Energy Upcycle — Tactical Long with Defined Stops
Specialty metals maker showing stable revenue, improving margins and cash conversion; trade idea with entry, stop and two target bands.
ATI Inc. is benefitting from durable macro tailwinds in aerospace aftermarket/OEM ramps, defense spending and power/energy demand. Recent quarter (Q3 ...
Milestone Pharmaceuticals - Why 'Sell the News' After CARDAMYST Approval Is a Mistake
Approval is the start of a commercial story, not the finish line - balance sheet and pipeline support a tactical long.
Milestone (MIST) just cleared the biggest binary risk with FDA approval of CARDAMYST (etripamil). The market's reflexive 'sell the news' move ignores ...
Buy CRCL: USDC Float Growth and Interest Income Set Up a Re-rate
Actionable trade: scale in on weakness, stop-loss below $72, targets at $110 and $150—time horizon 3–12 months.
Circle deserves attention after a Q3 2025 earnings profile that shows reserve growth, larger interest income and a swing to profitability. The balance...
Apple (AAPL) - A Pre‑Earnings Long with Asymmetric Upside
Strong cash flow, ongoing buybacks and AI sentiment set the stage for an earnings beat — small position ahead of results, tighten or add after catalyst
Apple is trading around $260 with a healthy operating profile: recent quarter revenue $94.04B, operating income $28.20B and continued buybacks that ar...
Brookfield Asset Management: A $100 Target Backed by Cash Flow, AUM Scale and a Growing Dividend
A pragmatic long trade on BAM: buy on weakness, target meaningful re-rating as private-asset conversion and cash generation accelerate
Brookfield Asset Management (BAM) is an alternative-asset giant with USD 1.151 trillion of total managed assets and strong fee-earning scale (USD 580....
Buy the Pullback: Stoke Therapeutics After an FDA Delay - Zorevunersen's Long-Term Value Intact
A measured long idea: regulatory timing noise shouldn't obscure a near-term commercialization runway for zorevunersen.
Stoke Therapeutics (STOK) faces a near-term regulatory delay for its lead program, zorevunersen, but fundamentals and balance-sheet dynamics support a...
Pfizer at a Discount: A High-Yield, Low-Multiple Long Trade for 2026
Yield, cash flow and recent trial data make PFE an asymmetric value trade—here's an entry, stops and two target levels
Pfizer (PFE) trades near $25.5 with an implied market cap of roughly $145B, generates strong operating cash flow and pays a ~6.7% dividend. Recent cli...